Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now later-stage tilt small index

Vaginal Atrophy: later-stage trial registry

4 of 10 indexed Vaginal Atrophy trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Vaginal Atrophy: 10 US clinical trials tracked, 4 recruiting.

Vaginal Atrophy is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Stratpharma, running 2 of these trials.

Enrollment posture brief

Registry condition vaginal-atrophy

OPEN 4 | RECR 40% | LATE 6 | EARLY 0 | RANK #1724 | SPON 2

Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Vaginal Atrophy (this)40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Vaginal Atrophy

Vaginal Atrophy lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Vaginal Atrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Vaginal Atrophy is recruiting below its size-band peers.

    4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Vaginal Atrophy research.

    Stratpharma accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Vaginal Atrophy enrolment sits around 100 participants.

    Median target enrolment is 100 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.

  4. Vaginal Atrophy research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 32Phase 44

Open and recent trials

10 total, page 1 of 1

RECRUITING NA 2,000 participants

VALOR: Vaginal Atrophy & Long-term Observation of Recovery

Stratpharma

NCT05953090

RECRUITING Phase 4 100 participants

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

Maimonides Medical Center

NCT04807894

RECRUITING Phase 4 100 participants

Postpartum Vaginal Estrogen for Breastfeeding Patients

University Hospitals Cleveland Medical Center

NCT05457972

RECRUITING Phase 4 10 participants

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

Stratpharma

NCT07346287

ACTIVE NOT RECRUITING NA 30 participants

PRP Injections for Genitourinary Syndrome of Menopause

Medstar Health Research Institute

NCT06028009

COMPLETED Phase 3 650 participants

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

Wyeth is now a wholly owned subsidiary of Pfizer

NCT00238732

COMPLETED Phase 3 218 participants

Topical DHEA Against Vaginal Atrophy

EndoCeutics

NCT01846442

COMPLETED NA 60 participants

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

Sciton

NCT03178825

COMPLETED Phase 4 25 participants

Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy

University of Alabama at Birmingham

NCT03996603

COMPLETED NA 15 participants

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

Alma Lasers

NCT02747641

Phase Distribution

PhaseTrial count
Phase 3 2
Phase 4 4

Named interventions

Most-linked intervention names on Vaginal Atrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pixel CO2 Laser System Procedure
1 trials
Hybrid Fractional Laser Device
1 trials
Conjugated Estrogens Cream Drug
1 trials
Bazedoxifene/Conjugated Estrogen Drug
1 trials
Dhea (1.0%) Drug
1 trials
Dhea (0.5%) Drug
1 trials
Dhea (0.25%) Drug
1 trials
Injection of saline Procedure
1 trials

US sites by state

Facility locations filed on Vaginal Atrophy trials. A trial with sites in several states counts in each.

Florida 4 trials
California 4 trials
Alabama 3 trials
Virginia 2 trials
Texas 2 trials
Ohio 2 trials
North Carolina 2 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Vaginal Atrophy page

10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Vaginal Atrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Stratpharma sponsors the most Vaginal Atrophy trials on record, review their full trial history before evaluating a specific study. See Stratpharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vaginal Atrophy condition card totals 10 registered trials; most-linked intervention Pixel CO2 Laser System; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.